Vaccination against IL-31 for the treatment of atopic dermatitis in dogs

[...]the here-presented breakthrough therapy of vaccination against IL-31 is not only a promising mode to treat AD in dogs but may also facilitate the development of a similar vaccine in humans. Apoquel from Zoetis, the best current standard for the treatment of AD-induced pruritus in dogs, targets...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of allergy and clinical immunology Ročník 142; číslo 1; s. 279 - 281.e1
Hlavní autori: Bachmann, Martin F., Zeltins, Andris, Kalnins, Gints, Balke, Ina, Fischer, Nina, Rostaher, Ana, Tars, Kaspars, Favrot, Claude
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Elsevier Inc 01.07.2018
Elsevier Limited
Predmet:
ISSN:0091-6749, 1097-6825, 1097-6825
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract [...]the here-presented breakthrough therapy of vaccination against IL-31 is not only a promising mode to treat AD in dogs but may also facilitate the development of a similar vaccine in humans. Apoquel from Zoetis, the best current standard for the treatment of AD-induced pruritus in dogs, targets Janus kinase 1, a downstream molecule of a number of cytokines including those pivotal for the allergic reaction, including IL-31.3 In animals and humans, IL-4 and IL-13 are known to be critical for the inflammatory process in AD, while IL-31 is pivotal for the itching.1 Furthermore, an mAb against IL-31 has recently been approved for the treatment of AD in dogs.4 Both Apoquel as well as the mAb against IL-31 have to be given relatively frequently (twice daily for Apoquel and monthly for the antibody). [...]vaccination against IL-31, which should induce a more sustained antibody response, may be a valuable addition or alternative to existing therapies. Dogs were immunized with 100 μg CMVTT formulated in alum on day 0. Because the vaccine was well tolerated and caused no itching, the dose was increased to 300 μg on weeks 3 and 6 (see Fig 1, B, for study outline).
AbstractList [...]the here-presented breakthrough therapy of vaccination against IL-31 is not only a promising mode to treat AD in dogs but may also facilitate the development of a similar vaccine in humans. Apoquel from Zoetis, the best current standard for the treatment of AD-induced pruritus in dogs, targets Janus kinase 1, a downstream molecule of a number of cytokines including those pivotal for the allergic reaction, including IL-31.3 In animals and humans, IL-4 and IL-13 are known to be critical for the inflammatory process in AD, while IL-31 is pivotal for the itching.1 Furthermore, an mAb against IL-31 has recently been approved for the treatment of AD in dogs.4 Both Apoquel as well as the mAb against IL-31 have to be given relatively frequently (twice daily for Apoquel and monthly for the antibody). [...]vaccination against IL-31, which should induce a more sustained antibody response, may be a valuable addition or alternative to existing therapies. Dogs were immunized with 100 μg CMVTT formulated in alum on day 0. Because the vaccine was well tolerated and caused no itching, the dose was increased to 300 μg on weeks 3 and 6 (see Fig 1, B, for study outline).
Author Favrot, Claude
Zeltins, Andris
Tars, Kaspars
Bachmann, Martin F.
Kalnins, Gints
Rostaher, Ana
Balke, Ina
Fischer, Nina
Author_xml – sequence: 1
  givenname: Martin F.
  surname: Bachmann
  fullname: Bachmann, Martin F.
  email: martin.bachmann@me.com
  organization: RIA Immunology, Inselspital, University of Bern, Bern, Switzerland
– sequence: 2
  givenname: Andris
  surname: Zeltins
  fullname: Zeltins, Andris
  organization: Latvian Biomedical Research & Study Centre, Riga, Latvia
– sequence: 3
  givenname: Gints
  surname: Kalnins
  fullname: Kalnins, Gints
  organization: Latvian Biomedical Research & Study Centre, Riga, Latvia
– sequence: 4
  givenname: Ina
  surname: Balke
  fullname: Balke, Ina
  organization: Latvian Biomedical Research & Study Centre, Riga, Latvia
– sequence: 5
  givenname: Nina
  surname: Fischer
  fullname: Fischer, Nina
  organization: Vetsuisse Faculty, Dermatology Unit, University of Zurich, Wonterthurerstrasse, Zurich, Switzerland
– sequence: 6
  givenname: Ana
  surname: Rostaher
  fullname: Rostaher, Ana
  organization: Vetsuisse Faculty, Dermatology Unit, University of Zurich, Wonterthurerstrasse, Zurich, Switzerland
– sequence: 7
  givenname: Kaspars
  surname: Tars
  fullname: Tars, Kaspars
  organization: Latvian Biomedical Research & Study Centre, Riga, Latvia
– sequence: 8
  givenname: Claude
  surname: Favrot
  fullname: Favrot, Claude
  organization: Vetsuisse Faculty, Dermatology Unit, University of Zurich, Wonterthurerstrasse, Zurich, Switzerland
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29627081$$D View this record in MEDLINE/PubMed
BookMark eNqFkT1vFDEQhi0URC6BP0CBLNHQ7OKPXXuNaKIISKSTaIDWmvPOBi979mH7kPLv8XFJc0WoRiM9z2j0vhfkLMSAhLzmrOWMq_dzO4PzrWBct1y0xnTPyIozoxs1iP6MrBgzvFG6M-fkIueZ1V0O5gU5F0YJzQa-Ijc_wDkfoPgYKNyBD7nQ23UjOZ1iouUn0pIQyhZDoXGiUOLOOzpi2lan-Ex9oGO8yy_J8wmWjK8e5iX5_vnTt-ubZv31y-311bpxnTalERoFuAFg4iPwjXSdQBCscyMY0J3iDFTPpZSTGt0wjAMHxVFsWKcHJXsnL8m7491dir_3mIvd-uxwWSBg3GcrmJAd00PfVfTtCTrHfQr1u0opKbg2va7Umwdqv9niaHfJbyHd28eMKjAcAZdizgkn63z5F1hJ4BfLmT3UYWd7qMMe6rBc2FpHVcWJ-nj9SenjUcIa4x-PyWbnMTgcfUJX7Bj90_qHE90tPngHyy-8_5_8FwSYtMQ
CitedBy_id crossref_primary_10_3390_pathogens12121388
crossref_primary_10_1136_jitc_2022_004643
crossref_primary_10_1002_eji_201847810
crossref_primary_10_1080_14760584_2019_1557522
crossref_primary_10_1111_jdv_15972
crossref_primary_10_4168_aair_2021_13_1_23
crossref_primary_10_3390_v12030270
crossref_primary_10_1002_anie_202013189
crossref_primary_10_1111_vde_13344
crossref_primary_10_1016_j_molmed_2020_01_007
crossref_primary_10_1016_j_jaci_2019_01_050
crossref_primary_10_3389_fimmu_2020_01697
crossref_primary_10_1038_s41423_022_00897_8
crossref_primary_10_1111_vde_13192
crossref_primary_10_3390_vetsci8070124
crossref_primary_10_1111_imr_12863
crossref_primary_10_1111_all_16090
crossref_primary_10_1016_j_jaci_2024_08_010
crossref_primary_10_3389_fmicb_2018_02522
crossref_primary_10_1186_s40425_019_0587_z
crossref_primary_10_1111_all_15080
crossref_primary_10_3390_vaccines12060661
crossref_primary_10_1111_all_16530
crossref_primary_10_1111_vde_13319
crossref_primary_10_1002_ange_202013189
crossref_primary_10_1111_vde_70009
crossref_primary_10_3389_fimmu_2020_594911
crossref_primary_10_1155_2020_2061609
crossref_primary_10_58833_bozokvetsci_1704617
crossref_primary_10_1111_jvp_70022
crossref_primary_10_3390_vaccines8010116
crossref_primary_10_1016_j_addr_2018_08_007
crossref_primary_10_3390_vaccines9040395
Cites_doi 10.1111/vde.12088
10.1038/mt.2015.227
10.1111/all.13239
10.1038/nri2868
10.1016/S0165-2427(01)00296-3
ContentType Journal Article
Copyright 2018 American Academy of Allergy, Asthma & Immunology
Copyright Elsevier Limited Jul 2018
Copyright_xml – notice: 2018 American Academy of Allergy, Asthma & Immunology
– notice: Copyright Elsevier Limited Jul 2018
DBID AAYXX
CITATION
NPM
7SS
7T5
H94
K9.
NAPCQ
7X8
DOI 10.1016/j.jaci.2017.12.994
DatabaseName CrossRef
PubMed
Entomology Abstracts (Full archive)
Immunology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
Entomology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList Entomology Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-6825
EndPage 281.e1
ExternalDocumentID 29627081
10_1016_j_jaci_2017_12_994
S0091674918301180
Genre Letter
Research Support, Non-U.S. Gov't
Correspondence
Letter to the Editor
GeographicLocations United States--US
Europe
GeographicLocations_xml – name: United States--US
– name: Europe
GroupedDBID ---
--K
--M
-~X
.1-
.55
.FO
.GJ
.XZ
.~1
0R~
1B1
1P~
1RT
1~.
1~5
354
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
71M
8F7
8FE
8FH
8P~
9JM
AAAJQ
AABNK
AAEDT
AAEDW
AAFWJ
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABJNI
ABLJU
ABMAC
ABMZM
ABOCM
ABWVN
ABXDB
ACDAQ
ACGFO
ACGFS
ACIEU
ACLOT
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADFRT
ADMUD
ADNMO
ADVLN
ADXHL
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AFFNX
AFJKZ
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGEKW
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AHMBA
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
BPHCQ
BVXVI
C45
CAG
CJTIS
COF
CS3
DU5
EBS
EFJIC
EFKBS
EFLBG
EJD
EO8
EO9
EP2
EP3
EX3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HDU
HMK
HMO
HVGLF
HZ~
IHE
J1W
J5H
K-O
KOM
L7B
LK8
LUGTX
M27
M41
MO0
N4W
N9A
O-L
O9-
O9~
OAUVE
OBH
ODZKP
OHH
OHT
OK0
OK1
OVD
OZT
P-8
P-9
P2P
PC.
PQQKQ
PROAC
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SJN
SPCBC
SSH
SSI
SSZ
T5K
TEORI
TWZ
UGJ
UNMZH
UV1
WH7
WOW
WUQ
X7M
XFW
YOC
YQI
YQJ
Z5R
ZGI
ZXP
ZY1
~02
~G-
~HD
~KM
AACTN
RIG
9DU
AAYXX
CITATION
NPM
7SS
7T5
H94
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c479t-27e2ac8aaf1da1b3c42ea204cda9a74610a651333f6dc88d81a61e2b0478635c3
ISICitedReferencesCount 34
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000437837500030&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0091-6749
1097-6825
IngestDate Thu Oct 02 10:28:54 EDT 2025
Tue Oct 07 06:39:27 EDT 2025
Thu Apr 03 07:26:17 EDT 2025
Tue Nov 18 21:16:35 EST 2025
Sat Nov 29 07:22:59 EST 2025
Sun Apr 06 06:53:19 EDT 2025
Tue Oct 14 19:35:42 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c479t-27e2ac8aaf1da1b3c42ea204cda9a74610a651333f6dc88d81a61e2b0478635c3
Notes SourceType-Scholarly Journals-1
ObjectType-Correspondence-2
content type line 14
ObjectType-Letter to the Editor-1
ObjectType-Article-2
ObjectType-Correspondence-1
content type line 23
OpenAccessLink http://www.jacionline.org/article/S0091674918301180/pdf
PMID 29627081
PQID 2063217957
PQPubID 105664
ParticipantIDs proquest_miscellaneous_2023407854
proquest_journals_2063217957
pubmed_primary_29627081
crossref_citationtrail_10_1016_j_jaci_2017_12_994
crossref_primary_10_1016_j_jaci_2017_12_994
elsevier_sciencedirect_doi_10_1016_j_jaci_2017_12_994
elsevier_clinicalkey_doi_10_1016_j_jaci_2017_12_994
PublicationCentury 2000
PublicationDate July 2018
2018-07-00
20180701
PublicationDateYYYYMMDD 2018-07-01
PublicationDate_xml – month: 07
  year: 2018
  text: July 2018
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: St. Louis
PublicationTitle Journal of allergy and clinical immunology
PublicationTitleAlternate J Allergy Clin Immunol
PublicationYear 2018
Publisher Elsevier Inc
Elsevier Limited
Publisher_xml – name: Elsevier Inc
– name: Elsevier Limited
References Cavelti-Weder, Timper, Seelig, Keller, Osranek, Lässing (bib7) 2016; 24
Accessed 2016.
Bachmann, Jennings (bib5) 2010; 10
Furue, Yamamura, Kido-Nakahara, Nakahara, Fukui (bib1) 2018; 73
Zoetis.com. Zoetis receives USDA license for CYTOPOINT. Available at
Hillier, Griffin (bib2) 2001; 81
Cosgrove, Wren, Cleaver, Walsh, Follis, King (bib3) 2013; 24
Zeltins, West, ZabelF, Turabi, Balke, Haas (bib6) 2017; 2
Bachmann (10.1016/j.jaci.2017.12.994_bib5) 2010; 10
Hillier (10.1016/j.jaci.2017.12.994_bib2) 2001; 81
Cavelti-Weder (10.1016/j.jaci.2017.12.994_bib7) 2016; 24
Furue (10.1016/j.jaci.2017.12.994_bib1) 2018; 73
Cosgrove (10.1016/j.jaci.2017.12.994_bib3) 2013; 24
10.1016/j.jaci.2017.12.994_bib4
Zeltins (10.1016/j.jaci.2017.12.994_bib6) 2017; 2
References_xml – volume: 81
  start-page: 147
  year: 2001
  end-page: 151
  ident: bib2
  article-title: The ACVD task force on canine atopic dermatitis (I): incidence and prevalence
  publication-title: Vet Immunol Immunopathol
– volume: 2
  start-page: 30
  year: 2017
  ident: bib6
  article-title: A robust modular technology opening up the use of vaccine approaches to block signalling and treat chronic diseases even under limiting conditions
  publication-title: Nat PG Vaccines
– reference: . Accessed 2016.
– volume: 73
  start-page: 29
  year: 2018
  end-page: 36
  ident: bib1
  article-title: Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis
  publication-title: Allergy
– volume: 24
  start-page: 587
  year: 2013
  end-page: 597
  ident: bib3
  article-title: A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel(R)) in client-owned dogs with atopic dermatitis
  publication-title: Vet Dermatol
– volume: 24
  start-page: 1003
  year: 2016
  end-page: 1012
  ident: bib7
  article-title: Development of an interleukin-1beta vaccine in patients with type 2 diabetes
  publication-title: Mol Ther
– reference: Zoetis.com. Zoetis receives USDA license for CYTOPOINT. Available at:
– volume: 10
  start-page: 787
  year: 2010
  end-page: 796
  ident: bib5
  article-title: Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
  publication-title: Nat Rev Immunol
– volume: 24
  start-page: 587
  year: 2013
  ident: 10.1016/j.jaci.2017.12.994_bib3
  article-title: A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel(R)) in client-owned dogs with atopic dermatitis
  publication-title: Vet Dermatol
  doi: 10.1111/vde.12088
– ident: 10.1016/j.jaci.2017.12.994_bib4
– volume: 24
  start-page: 1003
  year: 2016
  ident: 10.1016/j.jaci.2017.12.994_bib7
  article-title: Development of an interleukin-1beta vaccine in patients with type 2 diabetes
  publication-title: Mol Ther
  doi: 10.1038/mt.2015.227
– volume: 73
  start-page: 29
  year: 2018
  ident: 10.1016/j.jaci.2017.12.994_bib1
  article-title: Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis
  publication-title: Allergy
  doi: 10.1111/all.13239
– volume: 10
  start-page: 787
  year: 2010
  ident: 10.1016/j.jaci.2017.12.994_bib5
  article-title: Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri2868
– volume: 2
  start-page: 30
  year: 2017
  ident: 10.1016/j.jaci.2017.12.994_bib6
  article-title: A robust modular technology opening up the use of vaccine approaches to block signalling and treat chronic diseases even under limiting conditions
  publication-title: Nat PG Vaccines
– volume: 81
  start-page: 147
  year: 2001
  ident: 10.1016/j.jaci.2017.12.994_bib2
  article-title: The ACVD task force on canine atopic dermatitis (I): incidence and prevalence
  publication-title: Vet Immunol Immunopathol
  doi: 10.1016/S0165-2427(01)00296-3
SSID ssj0009389
Score 2.4312642
Snippet [...]the here-presented breakthrough therapy of vaccination against IL-31 is not only a promising mode to treat AD in dogs but may also facilitate the...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 279
SubjectTerms Antigens
Atopic dermatitis
Dermatitis
Dogs
Immunization
Quality of life
Skin diseases
Vaccination
Viruses
Title Vaccination against IL-31 for the treatment of atopic dermatitis in dogs
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0091674918301180
https://dx.doi.org/10.1016/j.jaci.2017.12.994
https://www.ncbi.nlm.nih.gov/pubmed/29627081
https://www.proquest.com/docview/2063217957
https://www.proquest.com/docview/2023407854
Volume 142
WOSCitedRecordID wos000437837500030&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: ScienceDirect Freedom Collection - Elsevier
  customDbUrl:
  eissn: 1097-6825
  dateEnd: 20200131
  omitProxy: false
  ssIdentifier: ssj0009389
  issn: 0091-6749
  databaseCode: AIEXJ
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe6DSFeEN8UxmQkxEuVKXE-nDwO1LGiUnjoUMWL5TjOSBXS0mXT_hr-Vu5qJ2FUK_DAS9QmsaP4fjmfz3f3I-QVj2SQK-U5YApzJwgSJHL3UsdNeermiU7dVK7JJvhkEs9myade70eTC3NZ8qqKr66S5X8VNZwDYWPq7D-Iu-0UTsBvEDocQexw_CvBf5ZKFcbHN5BnsPA_rwejMWjBNqKwCy7HIIB6sSzUINPGdi1MfOzCus83zVbkXlnZqk1tWmWBWSbXHPRvpPr6zRIwm1IFXQzxF13W1s2N8ZRFt58ky8peeFfYGlOms9LEEI0M13fjpvDiNqTV-s6a_JnNvC2wWJyIm8Klh9qoYTfhThSblOhWTwdsA5BW6xo-mo3ZwDgm5odzqQqM4uPo-U0MqfL10tuTj-L4dDwW0-Fs-nr53UFWMty9txQtO2SP8TABrbl3NBrO3ndlnf3YLLDsO9i0LBNB-PtjbzJ9blrarE2c6T1y1wqZHhlM3Sc9XT0gtz_Y6IuH5OQXaFELLbqGFgVoUYAWbaFFFzk10KIdtGhRUYTWI3J6PJy-PXEsE4ejAp7UDuOaSRVLmXuZ9FJfBUxL5gYqk4nkWLJfRkgU5OdRpuI4iz0ZeZqlWPoJLFrlPya71aLSTwllLPMyHbqRhoWHgiHLeZQmGsx8mcMf3SdeM0hC2TL1yJZSiiYecS5wYAUOrPCYgIHtk0HbZmmKtGy922_GXjTfCUyYAlCztVXYtrLGqTE6_9huvxGvsFriHK5HPoOpMOR98rK9DIodd-tkpRcXeA_zcZM9hC6eGFi0L8eQMguM-WfbO39O7nSf4j7ZrVcX-gW5pS5B4qsDssNn8YFF9E9fVsv5
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Vaccination+against+IL-31+for+the+treatment+of+atopic+dermatitis+in+dogs&rft.jtitle=Journal+of+allergy+and+clinical+immunology&rft.au=Bachmann%2C+Martin+F&rft.au=Zeltins%2C+Andris&rft.au=Kalnins%2C+Gints&rft.au=Balke%2C+Ina&rft.date=2018-07-01&rft.pub=Elsevier+Limited&rft.issn=0091-6749&rft.eissn=1097-6825&rft.volume=142&rft.issue=1&rft.spage=279&rft_id=info:doi/10.1016%2Fj.jaci.2017.12.994&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0091-6749&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0091-6749&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0091-6749&client=summon